Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Ibogaine/Adolescents

Ibogaine for Adolescents

2 papers and 0 clinical trials exploring ibogaine as a treatment for adolescents.

CompoundIndole Alkaloid

Ibogaine

A unique indole alkaloid with complex pharmacology, investigated primarily for its capacity to interrupt substance use disorders and withdrawal.

Full Ibogaine profile
IndicationApproximately 300 million adolescents worldwide.

Adolescents

Psychedelic use among adolescents presents a complex interplay between cultural context, potential therapeutic benefits, and risks associated with mental health. Recent research suggests that while Western perspectives are largely negative, there is a growing interest in the potential for psychedelics to support mental health treatment in this demographic, particularly in therapeutic settings.

Full Adolescents profile

Academic Research

2 papers
Open Accessindividual

Ibogaine Blocks Cue- and Drug-Induced Reinstatement of Conditioned Place Preference to Ethanol in Male Mice

In male mice, repeated oral ibogaine (10 or 30 mg/kg) did not produce conditioned place preference but blocked both cue‑ and drug‑induced reinstatement of ethanol‑conditioned place preference in priming‑injection and context‑re‑exposure tests. This indicates ibogaine at non‑rewarding doses may reduce relapse‑like alcohol seeking and warrants consideration as a potential treatment for alcohol use disorder.

Published
September 21, 2021
Journal
Frontiers in Pharmacology
Authors
Henriques, G. M., Anjos-Santos, A., Rodrigues, I. R., Nascimento-Rocha, V., Reis, H. S., Libarino-Santos, M., Barros-Santos, T., Yokoyama, T. S., Bertagna, N. B., Favoretto, C. A., Moraes, C. R., Cruz, F. C., Barbosa, P., Marinho, E. A. V., Oliveira-Lima, A. J., Berro, L. F.
Open Accessindividual

Long-term Follow-Up Outcomes of MDMA-assisted Psychotherapy for Treatment of PTSD: A Longitudinal Pooled Analysis of Six Phase 2 Trials

Pooled analysis of six phase 2 trials found that two to three MDMA‑assisted psychotherapy sessions produced large reductions in PTSD severity at 1–2 months (LS mean change −44.8; Cohen’s d = 1.58) with further small but significant improvement at least 12 months post‑treatment (LS mean change −5.2; d = 0.23). The proportion no longer meeting PTSD criteria rose from 56% at treatment exit to 67% at long‑term follow‑up, most participants reported lasting benefits (improved relationships and well‑being) and only a minority reported harms; phase 3 trials are underway to confirm these results.

Published
June 4, 2020
Journal
Psychopharmacology
Authors
Jerome, L., Feduccia, A. A., Wang, J. B., Hamilton, S., Yazar-Klosinski, B., Emerson, A., Mithoefer, M. C., Doblin, R.

Clinical Trials

0 trials

No clinical trials have been tagged with both Ibogaine and Adolescents yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all Ibogaine papers Search all Adolescents trials Full Ibogaine profile Full Adolescents profile